Program
Meloxicam
Also written as “HTX-011”, “N1539” and “Meloxicam tablet”.
Its studies are mostly in Pain, Postoperative · Osteoarthritis · Arthritis, Rheumatoid · Hernia, Inguinal · Pain, led by 16 companies.
Drug pageMeloxicam: every studyMany companies study it; this page follows only the 66 they lead. All 88 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheimits history only | 220 open or running | phase 4since Jul 4, 2014 | May 2, 2002 | none ahead |
| Heron Therapeuticsits history only | 161 open or running | phase 4since Oct 1, 2021 | Jun 9, 2015 | none ahead |
| Baudax Bioits history only | 70 open or running | phase 4since Mar 15, 2022 | Aug 31, 2015 | none ahead |
| Alkermesits history only | 30 open or running | phase 3since Sep 15, 2011 | Jul 23, 2009 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 20 open or running | phase 1since Jul 12, 2010 | Jul 12, 2010 | none ahead |
| Eurofarma Laboratoriosits history only | 20 open or running | phase 3since Apr 24, 2012 | Apr 24, 2012 | none ahead |
| Grünenthalits history only | 20 open or running | phase 3since Sep 22, 2014 | Mar 18, 2013 | none ahead |
| Hikma Pharmaceuticalsits history only | 20 open or running | no phasesince Jan 15, 2008 | Jan 15, 2008 | none ahead |
| Teva Pharmaceutical Industriesits history only | 20 open or running | phase 1since Feb 6, 2009 | Feb 6, 2009 | none ahead |
| Viatrisits history only | 20 open or running | phase 1since Mar 30, 2008 | Mar 30, 2008 | none ahead |
| GlaxoSmithKlineits history only | 10 open or running | no phasesince Nov 28, 2012 | Nov 28, 2012 | none ahead |
| Joint Stock Company "Farmak"its history only | 10 open or running | phase 1since Nov 15, 2021 | Nov 15, 2021 | none ahead |
| Pfizerits history only | 10 open or running | no phasesince Sep 6, 2011 | Sep 6, 2011 | none ahead |
| Sino Biopharmaceuticalits history only | 11 open or running | phase 2since Jul 10, 2023 | Jul 10, 2023 | none ahead |
| Yangtze River Pharmaceutical Groupits history only | 10 open or running | phase 3since Mar 25, 2025 | Mar 25, 2025 | none ahead |
| Zodiac Produtos Farmaceuticosits history only | 10 open or running | phase 3since May 11, 2015 | May 11, 2015 | none ahead |
Also a collaborator on its studies: Eurotrials Brasil Consultores Cientificos Ltda.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 44 studies since Jan 15, 2008.
- Sep 24, 2018Phase 1 study in HealthyBoehringer Ingelheim · NCT03684265 · 26 enrolled · Russian Federation
- Oct 1, 20182 phase 2 studies in Pain, PostoperativeHeron Therapeutics · NCT03695367, NCT03718039
- Apr 5, 2019Phase 3 study in AgnosiaHeron Therapeutics · NCT03907176 · 209 enrolled · United States
- Apr 17, 2019Phase 2 study in AgnosiaHeron Therapeutics · NCT03922048
- Apr 29, 2019Phase 3 study in Osteoarthritis, KneeEurofarma Laboratorios · NCT03936192
- May 9, 2019Phase 2 study in Pain, PostoperativeHeron Therapeutics · NCT03955211 · 25 enrolled · United States
- Jun 3, 2019Phase 3 study in AgnosiaHeron Therapeutics · NCT03974932 · 116 enrolled · United States
- May 27, 2021Phase 2 study in Pain, PostoperativeHeron Therapeutics · NCT04911062 · 32 enrolled · United States
- Oct 1, 2021Phase 4 study in AgnosiaHeron Therapeutics · NCT05109312 · 90 enrolled · United States
- Nov 15, 2021Joint Stock Company "Farmak"’s first study: phase 1 study in PharmacokineticsNew to Joint Stock Company "Farmak"Joint Stock Company "Farmak" · NCT05125588 · 24 enrolled
- Mar 15, 2022Phase 4 study in Pain, PostoperativeBaudax Bio · NCT05315479 · 19 enrolled · United States
- Jul 10, 2023Sino Biopharmaceutical’s first study: phase 2 study in Pain, PostoperativeNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT05950152 · 108 planned · China
- Oct 25, 20232 phase 4 studies in Pain, PostoperativeHeron Therapeutics · NCT06109428, NCT06109415
- Mar 25, 2025Yangtze River Pharmaceutical Group’s first study: phase 3 study in Participants With Acute Moderate to Severe Pain Following Abdominal SurgeryNew to Yangtze River Pharmaceutical GroupYangtze River Pharmaceutical Group · NCT06904248 · 224 enrolled · China
TargetBeta
“Cyclooxygenase-2 inhibitor”ChEMBL 37, by rule
Other programs on PTGS2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Acetaminophenrule | Johnson & Johnson | phase 4 | 136 |
| Ibuprofenrule | Pfizer | phase 4 | 113 |
| Aspirinrule | Bayer | phase 4 | 84 |
| Celecoxibrule | Viatris | phase 4 | 78 |
| Etoricoxibrule | Organon | phase 4 | 35 |
| dexketoprofenrule | Menarini Group | phase 4 | 8 |
| Sulfasalazinerule | Bristol-Myers Squibb | phase 4 | 7 |
| dexibuprofenrule | aponia-laboratories-inc | phase 4 | 6 |
| Benzydaminerule | Angelini Pharma | phase 4 | 4 |
| Dipyronerule | Hypera Pharma | phase 4 | 4 |
| Piroxicamrule | Taisho Pharmaceutical | phase 4 | 4 |
| Flurbiprofenrule | GlaxoSmithKline | phase 3 | 12 |
Studies
The newest 60 of 66 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06904248Participants With Acute Moderate to Severe Pain Following Abdominal Surgery · China | 3 | Completed | Yangtze River Pharmaceutical Group | Nov 20, 2024 | 224 |
| NCT06109428Pain, Postoperative · United States | 4 | Completed | Heron Therapeutics | Mar 29, 2022 | 37 |
| NCT06109415Pain, Postoperative · United States | 4 | Completed | Heron Therapeutics | Jul 18, 2022 | 30 |
| NCT05950152Pain, Postoperative · China | 2 | Not yet recruiting | Sino Biopharmaceutical | Dec 2023 | 108 |
| NCT05315479Pain, Postoperative · United States | 4 | Terminated | Baudax Bio | Jul 7, 2022 | 19 |
| NCT05125588Pharmacokinetics | 1 | Completed | Joint Stock Company "Farmak" | Feb 26, 2014 | 24 |
| NCT05109312Agnosia · United States | 4 | Active, not recruiting | Heron Therapeutics | Jun 2024 | 90 |
| NCT04911062Pain, Postoperative · United States | 2 | Completed | Heron Therapeutics | Jul 29, 2022 | 32 |
| NCT03974932Agnosia · United States | 3 | Completed | Heron Therapeutics | Dec 7, 2020 | 116 |
| NCT03955211Pain, Postoperative · United States | 2 | Completed | Heron Therapeutics | Dec 3, 2021 | 25 |
| NCT03936192Osteoarthritis, Knee | 3 | Withdrawn | Eurofarma Laboratorios | Feb 2021 | 0 |
| NCT03922048Agnosia | 2 | Withdrawn | Heron Therapeutics | Nov 2025 | 0 |
| NCT03907176Agnosia · United States | 3 | Completed | Heron Therapeutics | Oct 25, 2021 | 209 |
| NCT03718039Pain, Postoperative · United States | 2 | Completed | Heron Therapeutics | Jan 31, 2019 | 78 |
| NCT03695367Pain, Postoperative · United States | 2 | Completed | Heron Therapeutics | Nov 20, 2018 | 63 |
| NCT03684265Healthy · Russian Federation | 1 | Completed | Boehringer Ingelheim | Oct 30, 2018 | 26 |
| NCT03434275Pain, Postoperative · United States | 3 | Completed | Baudax Bio | May 21, 2019 | 194 |
| NCT03323385Pain, Postoperative · United States | 3 | Completed | Baudax Bio | Sep 26, 2018 | 57 |
| NCT03295721Pain, Postoperative · United States | 3 | Completed | Heron Therapeutics | Jan 8, 2018 | 412 |
| NCT03237481Pain, Postoperative · United States, Belgium | 3 | Completed | Heron Therapeutics | Dec 22, 2017 | 418 |
| NCT03015532Pain, Postoperative · United States | 2 | Completed | Heron Therapeutics | Apr 20, 2018 | 285 |
| NCT03011333Pain, Postoperative · United States | 2 | Completed | Heron Therapeutics | Feb 1, 2018 | 243 |
| NCT02720692Pain, Postoperative · United States, Australia, Canada and more | 3 | Completed | Baudax Bio | Mar 2017 | 722 |
| NCT02678286Pain, Postoperative · United States | 3 | Completed | Baudax Bio | Oct 2016 | 219 |
| NCT02675907Pain, Postoperative · United States | 3 | Completed | Baudax Bio | Jul 2016 | 201 |
| NCT02540265Pain, Postoperative · United States | 2 | Completed | Baudax Bio | Nov 2015 | 59 |
| NCT02504580Pain, Postoperative · United States | 2 | Completed | Heron Therapeutics | Mar 2017 | 463 |
| NCT02471898Agnosia · United States | 2 | Completed | Heron Therapeutics | Sep 2015 | 71 |
| NCT02448199Osteoarthritis | 3 | UNKNOWN | Zodiac Produtos Farmaceuticos | Jun 2016 | 375 |
| NCT02255045Dysmenorrhea · Chile | 3 | Completed | Grünenthal | Feb 21, 2016 | 68 |
| NCT02229747Pharyngitis | 4 | Completed | Boehringer Ingelheim | Feb 2002 | 128 |
| NCT02187575Healthy | 1 | Completed | Boehringer Ingelheim | Sep 2002 | 26 |
| NCT02187562Healthy | 1 | Completed | Boehringer Ingelheim | Aug 2002 | 16 |
| NCT02183181Healthy | 1 | Completed | Boehringer Ingelheim | Jan 2009 | 6 |
| NCT02183168Spondylitis, Ankylosing | 3 | Completed | Boehringer Ingelheim | May 1, 2002 | 192 |
| NCT02183129Osteoarthritis | 4 | Completed | Boehringer Ingelheim | Nov 1, 1999 | 91 |
| NCT02183116Osteoarthritis | 4 | Completed | Boehringer Ingelheim | Feb 1999 | 30 |
| NCT02183077Healthy | 1 | Completed | Boehringer Ingelheim | Nov 1998 | 12 |
| NCT02183064Osteoarthritis | 3 | Completed | Boehringer Ingelheim | Nov 2000 | 1,309 |
| NCT02183051Pain | 2 | Completed | Boehringer Ingelheim | Oct 1998 | 381 |
| NCT02183025Dysmenorrhea | 2 | Completed | Boehringer Ingelheim | Apr 1999 | 337 |
| NCT02181907Healthy | 1 | Completed | Boehringer Ingelheim | Apr 2003 | 22 |
| NCT02181322Healthy | 1 | Completed | Boehringer Ingelheim | Sep 2001 | 24 |
| NCT02181309Healthy | 1 | Completed | Boehringer Ingelheim | Apr 2002 | 24 |
| NCT02180490Healthy | 1 | Completed | Boehringer Ingelheim | Jul 2002 | 60 |
| NCT02180477Healthy | 1 | Completed | Boehringer Ingelheim | Dec 2001 | 9 |
| NCT01839643Contraception · Chile | 1 | Completed | Grünenthal | May 7, 2013 | 13 |
| NCT01750931Arthritis, Rheumatoid | – | Completed | GlaxoSmithKline | Oct 1, 2013 | 28 |
| NCT01587508Acute Lumbago · Brazil | 3 | Withdrawn | Eurofarma Laboratorios | May 2013 | 0 |
| NCT01436032Laparoscopic Surgery · United States | 3 | Terminated | Alkermes | Mar 2012 | 50 |
| NCT01430559Osteoarthritis, Knee · China | – | Completed | Pfizer | Mar 27, 2013 | 408 |
| NCT01161147Healthy · Canada | 1 | Completed | Dr. Reddy's Laboratories | Dec 2004 | 28 |
| NCT01161134Healthy · Canada | 1 | Completed | Dr. Reddy's Laboratories | Nov 2004 | 28 |
| NCT01084161Hysterectomy · Georgia, Poland, Serbia | 2 | Completed | Alkermes | Jan 2011 | 486 |
| NCT00945763Toothache · United States | 2 | Completed | Alkermes | Nov 2009 | 230 |
| NCT00840879Healthy · Canada | 1 | Completed | Teva Pharmaceutical Industries | Feb 2004 | 28 |
| NCT00840476Healthy · Canada | 1 | Completed | Teva Pharmaceutical Industries | Feb 2004 | 28 |
| NCT00649675Healthy · United States | 1 | Completed | Viatris | Sep 2004 | 27 |
| NCT00649077Healthy · United States | 1 | Completed | Viatris | Sep 2004 | 30 |
| NCT00618163Inflammation · United States | – | Completed | Hikma Pharmaceuticals | Apr 2005 | 47 |
How it is read
Names in the registry
- “HTX-011”, 20 entries
- “N1539”, 18 entries
- “Meloxicam”, 12 entries
- “Meloxicam tablet”, 3 entries
- “Meloxicam 15 mg Tablets”, 2 entries
Conditions, from the studies’ own filings
- Pain, Postoperative, 21 studies
- Osteoarthritis, 6 studies
- Arthritis, Rheumatoid, 3 studies
- Hernia, Inguinal, 2 studies
- Pain, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.